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Abstract
The incidence of malignant melanoma continues to increase each year with poor prognosis
for survival in many relapse cases. To reverse this trend, whole body response measures
are needed to discover collaborative paths to primary and secondary malignancy. Several
species of fish provide excellent melanoma models because fish and human melanocytes
both appear in the epidermis, and fish and human pigment cell tumors share conserved
gene expression signatures. For the first time, we have examined the whole body transcrip-
tome response to invasive melanoma as a prelude to using transcriptome profiling to screen
for drugs in a medaka (Oryzias latipes) model. We generated RNA-seq data from whole
body RNA isolates for controls and melanoma fish. After testing for differential expression,
396 genes had significantly different expression (adjusted p-value <0.02) in the whole body
transcriptome between melanoma and control fish; 379 of these genes were matched to
human orthologs with 233 having annotated human gene symbols and 14 matched genes
that contain putative deleterious variants in human melanoma at varying levels of recur-
rence. A detailed canonical pathway evaluation for significant enrichment showed the top
scoring pathway to be antigen presentation but also included the expected melanocyte
development and pigmentation signaling pathway. Results revealed a profound down-regu-
lation of genes involved in the immune response, especially the innate immune system.
We hypothesize that the developing melanoma actively suppresses the immune system
responses of the body in reacting to the invasive malignancy, and that this mal-adaptive
response contributes to disease progression, a result that suggests our whole-body tran-
scriptomic approach merits further use. In these findings, we also observed novel genes not
yet identified in humanmelanoma expression studies and uncovered known and new candi-
date drug targets for further testing in this malignant melanoma medaka model.
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Introduction
While the incidence of most cancers is decreasing, malignant melanoma (MM) continues to
increase by 3–7% per year in Caucasians and has a 5-year survival rate of only 20% [1]. Melanoma
genome sequencing and exome sequencing of an astonishingly high heterogeneity of clinical sam-
ples have led to the identification of a large catalog of recurrent somatic variants [2], most notably
BRAF andNRAS. However, patient outcomes from treatment with novel compounds are compro-
mised by an almost 100% recurrence rate due to rapidly occurring drug resistance [3] and mela-
noma suppression remains unpredictable when targeting protein-coding genes identified in large
cohort sequencing projects. A deeper exploration of cause-and-effect melanomagenesis data is
urgently needed. At present, vertebrate melanomamodels exist for zebrafish, medaka, platyfish,
mouse, the Syrian hamster, Mongolian gerbil and opossum [4–7], each with its own advantages
and disadvantages for utility in drug discovery and molecular mimicry of humanmelanoma.
In contrast to humans, mice and other rodent skin is devoid of epidermal melanocytes as they
occupy the hair follicles and dermis, except for some in the skin of footpads, tail, ears and snout,
whereas fish melanomamodels mimic the appearance of melanocytes in the human epidermis.
Another advantage appears to be the lack of hair cycling which periodically changes the profile of
gene expression in skin and other organs, which complicates studies on tumor environment. Fish
models available in zebrafish and medaka have additional advantages, including easy transgen-
esis, superior suitability for bioimaging analyses due to the transparency of embryos and larvae
and importantly, their suitability for high throughput chemical screens [8, 9]. While single driver
gene melanoma models, such as medaka and zebrafish, are initially genetically less complex than
human melanomas, the expression signatures of zebrafish and medaka melanomas clearly show
common features with human melanoma [10, 11]. Fish models have proven their value for mela-
noma research and have become well-accepted tools for furthering our knowledge and for devel-
oping better diagnostic and therapeutic tools [7, 12].
Several studies have examined gene expression changes in zebrafish, medaka, mouse and
human melanomas [13–15]. A recent meta-analysis of human melanoma microarray data sug-
gested that 17 genes show aberrant expression [15]. All approaches [13–15] thus far reported
have dissected out melanoma tumor cells of various classifications, mostly from the metastatic
disease, and compared results to normal skin or melanocytic nevi. None of these studies mea-
sured the whole-body transcriptome in established melanoma and compared results to normal
individuals. This type of comparison is necessary because tumors also have effects on entire
organisms; furthermore, tissue systems throughout the organism play a role in tumor growth
and disease, especially the vasculature, endocrine, and immune systems [12, 16]. Melanoma is
a highly invasive and metastatic tumor where already early on, small nests or single tumor cells
colonize the whole body. This is further complicated by the fact that these microtumors are
often non-pigmented and reside far away from the primary lesion, making them easy to over-
look even by an experienced experimenter. Therefore, our strategy was to compare the tran-
scriptomes of intact melanoma fish rather than dissecting the melanoma from the “healthy”
part of the individual. This strategy allowed for the establishment of a melanoma transcrip-
tional disease signature and identified disregulation of various canonical pathways that may
indicate a systemic response to the spread of malignant melanocytes.
Material and Methods
Sequencing
A transgenic melanoma model in medaka (Oryzias latipes) was used to determine the tran-
scriptional disease signature (TDS) of melanoma. In this model, the oncogenic receptor
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tyrosine kinase Xmrk, which is encoded by the melanoma-inducing gene from the platyfish
(Xiphophorus maculatus), is specifically expressed in pigment cells under control of the
medakamitf promoter [17]. The stably integrated transgene was introduced into an inbred
strain (Carbio) of medaka by introgressive breeding. Fish were kept under standard conditions
in the aquarium facility of the Biozentrum at the University of Würzburg and all studies were
approved by the Institutional Review Board. For RNA-seq experimentation, total RNA was
extracted from the intact bodies of size-matched (1cm total length) non-transgenic and trans-
genic fish 3–5 weeks old using an RNeasy Qiagen kit (Venlo, Netherlands) according to the
manufacturers’ protocol. To compare gene expression between controls and melanoma fish, a
biological sample was prepared and sequenced individually from four individual melanoma
fish and four individual control fish, thus providing four independent biological replicates of
each condition. We checked total RNA for quality on the Agilent Fragment Analyzer, then
enriched for poly(A)+ RNA using the MicroPolyA Purist kit (Ambion, Carlsbad, CA). We
used ScripSeq (Epicentre, Madison, WI) to generate strand-specific cDNA that was sequenced
on the Illumina Hiseq2000 platform as 100 base paired-end reads (insert size of 400bp). All
sequences are available under accession number PRJNA219474.
Differential gene expression
Across samples, an average of 34.5 million read pairs with average base quality>35.7 were
obtained after filtering for duplicates and low quality bases. Sequences from each sample were
mapped to medaka transcripts (Ensembl version 80) using TopHat2 [18]. A custom perl script,
available on request, was used to count mapped reads per each transcript in each sample.
DESeq2 was used to analyze read count data from the previous step and to identify differential
expression levels based on an error model that uses the negative binomial distribution[19]. In
this study for all control to tumor gene comparisons we used an adjusted p-value of<0.02 as
our significance threshold for further biological inference.
RNA-seq validation
For confirmation of RNA-seq data, selected genes were assayed with qPCR from ten control
and ten melanoma fish individually (siblings of fish used for the RNA-seq experiments and
two melanoma fish that were also used for the RNA-seq). RNA was isolated from whole fish
bodies using the RNeasy Mini Kit (Qiagen, Venlo, Netherlands) according to the manufactur-
ers’ protocol. cDNA was prepared from total RNA using the RevertAid kit (Fermentas, Wal-
tham, MA) with random hexamer primers. 25 ng of each cDNA was analyzed in triplicate in a
25 μl volume using a SYBR green-containing mastermix for 5 min at 95°C followed by 40 cycles
of 95°C for 30 s, 60°C for 30 s and 72°C for 20 s in a mastercycler ep realplex (Eppendorf, Ham-
burg Germany). Expression of each gene was normalized to ef1a1 levels, a positive control
gene, and fold changes were calculated versus one wild-type fish. All p-values were calculated
by applying the Mann-Whitney-U-test.
Pathway and transcription regulator enrichment
To infer further functional information from malignant melanoma whole body transcriptomes,
it was necessary to match each regulated medaka gene to its human ortholog and, when possi-
ble, affiliated human gene symbol. Of 396 differentially regulated medaka genes (adjusted p
value< .02), we were able to obtain 233 medaka genes with matching human gene annotation,
a prerequisite for many statistical tests of functional enrichment. We used a combination of
human orthology retrieval through the Ensembl BioMart tools (a predefined set of multispecies
orthologs) and manual alignment curation by BLAST to derive this set. It is recognized in
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some cases that an additional copy of each gene could be present in the medaka genome
because teleosts experienced an additional unique whole genome duplication event [20, 21].
The human gene symbols and log ratio values for each differentially expressed medaka gene
were input into the Ingenuity core analysis software [22]. We then performed canonical path-
way enrichment and upstream regulatory activation analyses. To measure statistical signifi-
cance for over-represented canonical pathways, we used a right-tailed Fisher’s exact test (p-
value cutoff< .01). To ascertain transcription regulators that could explain observed gene
expression changes, we relied on two test statistics 1) a p-value overlap score was calculated
with a Fishers exact test, whereby a statistical overlap is calculated between differentially
expressed genes and the known targets of the transcription regulators (p-value cutoff< .01)
and 2) a activation z-score that attempts to infer activation states based on prior knowledge of
regulation by the regulator compared to a random model of regulation, a z-score of greater
than 2 or less than -2 were considered significant [22].
Drug interaction
To discover genes that could be targeted with known drugs, we input the 233 medaka expres-
sion candidates with human orthologs into the DGIdb database (http://dgidb.genome.wustl.
edu) and performed a search with default screen parameters to find all gene to drug interac-
tions using the antineoplastic filter [23].
Results
We used our transgenic medaka model (tg(mitf:xmrk)) for melanoma where the pigment cell-
transforming oncogene xmrk [24] isolated from the platyfish Xiphophorus maculatus was
placed under control of the medakamitf (microphthalmia-associated transcription factor) pro-
moter, which drives oncogene expression in melanocytes [17]. Themitf promoter confers
strong but strictly pigment cell-specific expression to the tumor-inducing driver-oncogene
xmrk with no ectopic or background expression [17, 25–27]. In the homogenous genetic back-
ground of the medaka strain used here (Fig 1A), transgenic juveniles start to develop highly
invasive extracutaneous malignant melanoma at late larval stages (3–4 weeks of age) with
almost 100% penetrance [17] (Fig 1B). At later stages (7–8 weeks), these melanomas progress
to metastatic disease with multiple large nodular and invasive tumors in the abdomen and
Fig 1. Transgenic medakamodel for melanoma in juvenile fish (a) Control sibling and (b) fish with themitf:xmrk transgene showing onset of
malignant melanoma spreading over the fins and invading the bodymusculature at 3–4 weeks age (c) fish at 8 weeks of age with invasive and
nodular melanoma. (d, e) Transverse sections through the posterior region of 4 weeks oldmitf:xmrk transgenic medaka. (d) Melanoma invasion
deep into the body trunkmusculature. (e) Nest of melanoma cells (white arrowhead) close to the spinal cord. Mmuscle bundles, Sc scale, SpC
spinal cord, black arrowheads point to stretches of invading melanoma cells, scale bars represent 50 μm in (d) and 20 μm in (e). (f) a nodular
melanoma in an adultmitf:xmrkmedaka. The white arrowhead points to an area with lowly differentiated melanoma cells and a black arrowhead indicates
a nest of heavily pigmented melanoma cells.
doi:10.1371/journal.pone.0143057.g001
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trunk musculature (Fig 1C). In the initial stage of melanoma development, the progression of
the malignant disease is mostly apparent by invasion of tumor cells deeply into the trunk mus-
culature, where they follow the space between single muscle bundles (Fig 1D). At multiple
extracutaneous sites proliferation of melanoma cells that arrived from elsewhere leads to
tumor nodules and lesion expansion (Fig 1E).
We generated RNA-seq data from whole body RNA isolates for four melanoma and four
control siblings at 3–4 weeks of age, a stage when the tumors switch from localized lesions to
progressive malignant disease. Transcript read counts>10 per individual in at least 50% of all
fish (control and tumor) were generated for 19,985 of 25,434 Ensembl medaka genes. After
read count normalization and statistical testing for differentially expressed genes [28], 396 of
medaka genes were found to have significantly different expression levels (adjusted p-
value<0.02) between melanoma and control fish. Among all differentially expressed genes, a
total of 233 matched human orthologs with descriptive gene annotation, which allowed for
putative biological inference, were considered further for statistical enrichment tests (Table A
in S1 File). Independent quantitative PCR validation of a sub-set of these regulated genes con-
firmed the direction of expression for a majority (6 of 8; Table B in S1 File). We purposefully
chose genes of importance to melanoma biology (irf1, atm), immune systems (tlr2, stat4) and
others of unknown melanoma association but significantly regulated in our medaka model
(stc1, slc24a5, epd1, gadd45a). The reason for non-validation is unknown, but several possibili-
ties exist, including paralogs confounding probe hybridization kinetics.
Overall in our study, more genes were down-regulated (n = 138) than up-regulated (n = 95)
in melanoma fish compared with controls (Table A in S1 File). Of this set, 14 matched human
genes shown to harbor recurrent somatic mutations [29] (Table C in S1 File). The upper and
lower log ratio expression extremes were +2.48 and -5.67 for fkbp5 and snord14c, respectively.
The role of snord14c in melanoma progression is unknown, as snord14c is a member of the
small nucleolar RNAs (snoRNAs) and is classified as a C/D box snoRNA that generally are
linked to methylation [30]. In contrast, fkbp5 is a member of the immunophilin protein family,
which play a role in immunoregulation and basic cellular processes involving protein folding
and trafficking and has been recently linked to melanoma dissemination [31].
We sought to validate our whole body transcriptome model by examining expression direc-
tionality of known molecular participants of the melanocyte development and pigmentation
signaling pathways. The expression levels of five gene members were significantly (adjusted
p-value< .02) elevated or decreased: shp, creb, pi3k, plcg2, and tyrp1 (Fig 2). As in other verte-
brates, medaka melanomas originate from neural crest-derived pigment synthesizing cells and
elevated expression ofmitf, a key transcriptional regulator in melanoma, has been functionally
linked to the neoplastic phenotype in humans[32]. However, in the whole body transcriptome,
themitf gene was up regulated two-fold in the melanoma fish but did not reach our p-value<
.02 significance threshold (adjusted p-value 0.19). Nonetheless, the pigmentation gene tyrp1
showed a elevated level of expression in the whole body of melanoma fish as a result ofmitf
upregulation (Fig 2; p-value<0.0001). Another upregulated gene is hypoxia inducible factor 3.
In mammalian melanocytes induction of melanin pigmentation led to upregulation of hif1α
expression and related pathways [33]. A well-established melanoma marker in dermatooncol-
ogy, pmel, was increased as well (adjusted p-value<0.00002). A striking and novel feature not
noted earlier in expression studies using dissected fish melanoma was a general down-regula-
tion of components of the innate immune system. Some other significant examples of note
include: interferon response factor 1 (irf1), several MHC, effectors of the cytotoxic T-cell
response including perforin (prf1), complement components (c3, c1qa) and cytokines (il12).
To discover programs of responses to invasive melanoma at its initial stage, we tested for
significant participation among signaling and metabolic pathways, molecular networks, and
Medaka Melanoma Transcriptome
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biological processes that are most perturbed in these juvenile melanoma fish [22]. A total of 46
pathways were considered further (p-value<0.01; Table D in S1 File). One of the significantly
scored pathways was melanocyte development and pigmentation (Fig 2; Table D in S1 File),
again validating our intact-fish approach for understanding organism-wide changes to gene
expression that are likely to be highly relevant for indirect correlation to human melanoma
progression. Two of the other highest scoring pathways were antigen presentation (p-value
0.0000014) and cytotoxic T lymphocyte-mediated apoptosis (p-value 0.000251). Antigen pre-
sentation is a vital process of the immune system with many cellular participants acting as sen-
tinels that oscillate between detecting self versus entities that disrupt body homeostasis, i.e.,
cancer. We found members b2m, cd74, hla-dqa1, hla-drb1, psmb9, and tap2 of this pathway to
all be down-regulated in melanoma fish (Table A in S1 File). After manual curation, a total of 6
of the top 10 scoring pathways (p-value<0.001; Table D in S1 File) were affiliated with the
immune system. To our knowledge this phenomenon was not observed in previous studies of
the fish melanoma models where dissected tumors were analyzed [11, 34, 35].
Fig 2. Genes known to be associated with melanocyte development and pigmentation signaling.Red and green colored gene symbols are increased
or decreased, respectively, in melanoma fishes compared to control. Themitf gene (yellow) is upregulated but fails to reach statistical significance.
doi:10.1371/journal.pone.0143057.g002
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To expand our systemic knowledge of whole body melanoma transcriptomes, we sought to
elucidate the putative upstream regulators of melanoma-expressed genes for probable states of
activation or inhibition that may provide testable hypotheses of downstream effects on mela-
noma sustainability (Table 1). We used the inferred activation states of transcriptional regula-
tors given the observed differential state of genes in our medaka melanoma model for this
purpose [22]. A z-score statistic was used to predict expression states, activated or inhibited,
that we set at -2 or +2 to reach significance. Given this threshold, we found 17 and 16 molecules
that predict an inhibitory or activated effect of a given regulator, respectively, on various
medaka genes expressed in this whole body melanoma model (Table 1). A cumulative list of all
molecules that met this statistical criteria are provided for further review (see S2 File). The
Table 1. Estimated activation state for inferredmelanoma gene network regulators.
Upstream
Regulator




Medaka melanoma gene network
count
IFN-gamma cytokine Inhibited -5.082 33
TNF cytokine Inhibited -3.173 24
CD40LG cytokine Inhibited -2.962 12
LPS chemical drug Inhibited -2.774 24
IRF7 transcription regulator Inhibited -2.63 7
IL1B cytokine Inhibited -2.626 17
IL15 cytokine Inhibited -2.583 11
STAT1 transcription regulator Inhibited -2.476 12
LFNAR group Inhibited -2.449 6
IRF1 transcription regulator Inhibited -2.361 9
CD40 transmembrane receptor Inhibited -2.356 6
IL2 cytokine Inhibited -2.253 12
Aldesleukin biologic drug Inhibited -2.219 5
RELA transcription regulator Inhibited -2.13 15
IFN-alpha group Inhibited -2.095 8
Cisplatin chemical drug Inhibited -2.064 10
Inosine chemical Inhibited -2 4
Alefacept biologic drug Activated 2 4
OTX2 transcription regulator Activated 2 4
CDKN2A transcription regulator Activated 2 5
SB203580 chemical—kinase inhibitor Activated 2.144 6
LNS1 other Activated 2.172 5
PRDM1 transcription regulator Activated 2.183 5




MAPK1 kinase Activated 2.219 6
APOE transporter Activated 2.226 7
Forskolin chemical toxicant Activated 2.236 15
Akt group Activated 2.236 5
RICTOR other Activated 2.236 5




IL10 cytokine Activated 2.751 9
doi:10.1371/journal.pone.0143057.t001
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three molecules of highest inferred inhibitory significance were ifnγ, cd40lg, and tnf-alpha.
Interestingly, we found that ifnγ is the top ranked upstream regulator of genes expressed in
medaka developing melanoma (z-score -5.08). These putatively ifnγ regulated genes (33 total)
span several overlapping molecular pathways as shown in a network based presentation (Fig A
in S1 File). The majority (82%) of the 33 differentially expressed medaka genes in melanoma
fish were down-regulated as part of our curated ifnγ regulatory network and all but one, ehf,
agree with expectations based on the Ingenuity curated expression database.
Thus far, fish have provided useful models for furthering our understanding of melanoma
biology and basic molecular mechanisms and for screening of potential drugs that act directly
on the tumor [36]. When all differentially regulated expression candidate genes with matching
human gene orthologs (n = 233) were examined for known drug to gene interactions, we found
10 genes with 73 unique drug interactions [23], with the phosphatidylinositol kinase gene
pik3r6 contributing 21 unique drug interactions (Fig 3). In addition, pik3r6 displays recurrent
somatic mutations in human melanoma and would thus be considered a high priority target in
future experiments designed to utilize drugs that target this gene in our melanoma fish and
observe therapeutic outcomes [29].
Discussion
The effects of genetic background on human malignancy progression is an important but
poorly understood phenomenon [37]. Our system provides a significant opportunity to explore
this problem and already its investigation has led to the identification of several melanoma
genes, including osteopontin [38], which now serves as a clinical marker for human disease
progression [39]. Among fish models, medaka presents as a unique feature the availability of
many highly inbred strains that allow one to study cancer formation in animals of the same or
a variety of different genetic backgrounds. Furthermore, the xmrk transgene on different
genetic backgrounds provides different types of melanoma [17] and transforms mouse and
human melanocytes [26, 27] that result in highly similar biochemical and genetic changes [10,
Fig 3. Number of unique drugs predicted to target each knownmedakamelanoma differentially
expressed gene. The drug list is presented in full in S3 File.
doi:10.1371/journal.pone.0143057.g003
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14], making this system ideal for identifying both genetic modifiers of tumor type and drugs
tailored to different genotypes. The pigment lesions in our mitf:xmrk transgenic medaka at the
time of RNA-seq sampling are clearly not just “local hyperpigmentation” in the dermis but an
aggressive malignancy that is located predominantly at extracutaneous sites, mainly as invasive
growth between the muscle fibers and bones. Melanoma cells contain black pigment, and due
to the transparency of the juvenile medaka, the area covered by melanin inside the fish in the
trunk is a good proxy for estimating the size of the tumor. Moreover, the single homologous
gene driver and the short time window in which tumors fully invade the whole body excludes
many types of secondary (passenger) mutations that might occur. To exploit this situation, we
explored the use of whole body transcriptome profiles to catalog gene candidates for therapeu-
tic intervention and to discover the body’s canonical pathway responses to highly invasive
melanoma.
The whole-body transcriptomes established in our study from melanoma-bearing trans-
genic medaka readily detected changes in canonical pathways known from studies on human
melanoma [40], but also show a clear differentiation from earlier RNA-seq analysis of mela-
noma biopsies from adult medaka fish [10]. We identified a considerable number of genes that
were not detected earlier when analyzing tumors in isolation [10]. For instance, snord14c
showed the strongest down-regulated state in the whole body melanoma transcriptome, yet its
role in melanoma formation is not understood to our knowledge, and thus identifies a new
putative candidate for the further understanding of the molecular mechanisms of melanoma
progression, perhaps highlighting a role for RNA methylation. The fkbp5 gene is another
example of a potential contributor to melanoma dissemination in this medaka expansion
model. Recent studies highlighted fkbp5 in the transformation of transforming growth factor-β
from a tumor suppressor to pro-metastatic aggressor, facilitating cancer cells ability to spread
to distant sites from the original primary tumor site [31].
Our whole body set of differentially expressed genes, critically collected when melanoma is
in invasive mode, allowed us to search for molecular pathways that are significantly enriched
in the melanoma developing fish. Given the transgenic initiation of melanocyte malignancy in
our model, it was predicted at least some known genes associated with this pathway would be
differentially regulated. The high scoring melanocyte pathway clearly shows that our whole
body transcriptome measures were sufficient to detect modulation of some member genes,
such as tyrp1, over whole body signal noise. The increase of tyrp1 expression is interesting
since melanin synthesis, melanogenesis and melanin pigment affect the behavior of normal
and malignant melanocytes. In melanoma cells melanogenesis is related to shorter survival of
patients [41]. More importantly, our results shine new light on the direct relevance of the
mechanisms by which immune gene networks respond or fail to respond to the expanding
population of malignant melanocytes and are likely highly relevant to human melanoma path-
ogenesis. As a consequence of melanocyte proliferation and spread, we hypothesize that intact
body systems attempt to identify and kill malignant melanocytes, but too often this alarm to
the immune system is insufficient to overcome a fast growth tumor trajectory, especially if cel-
lular cytoskeleton dynamics are not optimum. A heightened immune response could be com-
promised by reported immunosuppressive properties of malignant melanocytes [42]. In fact,
an important immune pathway, antigen presentation, was found to be enriched for several dif-
ferentially expressed medaka member genes and we observed down-regulation for all in the
melanoma state. This may indicate mechanisms of immune escape of the fish pigment cell
tumor in its initial stage and resembles conditions that have been noted also in human mela-
noma [43]. Further expansion of our list of statistically significant genes regulated within the
known immune signaling pathways is likely with deeper sequencing per whole body melanoma
isolate.
Medaka Melanoma Transcriptome
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The inability of the immune system to detect and react with sufficient intensity to check
progressive melanoma has confounded scientists. Some evidence suggests that melanoma has
an immunosuppressive capability [42, 44]. In particular, intermediates in melanin synthesis,
e.g. L-DOPA have immunosuppressive capability [45, 46]. We found several genes in our dif-
ferentially expressed gene set that, when examined at the network level, broadly suggest
immune system suppression; it will be important, however, to differentiate the mechanisms of
immunosuppressive or atypical inflammatory responses for these candidates. Within several
immune pathway classifications, such as antigen presentation, dendritic cell maturation, and
cytotoxic T lymphocyte-mediated apoptosis, we observe all but one gene showing decreased
expression in medaka melanoma. Together with the finding that most genes involved in
immune system pathways were down-regulated in this early progression phase of fish melano-
mas, this result suggests that immune evasion might be important for the invasive success of
malignant melanoma. Interestingly, a soluble form of pmel can protect melanoma cells from
antibody-mediated immunity [47], while the membrane-bound form activates the immune
response via dendritic cells [48]. While the transcript isoform of this gene was highly up-regu-
lated in our melanoma fishes, protein form responses will need to be measured to fully under-
stand the immunomodulatory consequences. Of note, in this study we believe the immune
suppressive state that we observed at a very early stage (3–4 weeks) of tumor formation
excludes the explanation that immune evasion is due to additional acquired mutations; rather,
it is an indigenous feature of melanoma cells.
Utilizing prior knowledge of expected directional relationships between transcriptional reg-
ulators of all types (drugs, transcription factors, small molecules, etc.) and downstream
expressed genes is a powerful model for high-level melanoma gene network inference (Fig A in
S1 File). Our analysis of known upstream regulators strongly suggests that melanoma fish
experience a robust suppression of the ifnγ responsive gene network, the highest scoring net-
work in this study. Recently, an unexpected connection between the immune cytokine ifnγ and
skin pigmentation homeostasis was found [49] mediated through the transcription factor irf1,
a gene that we find consistently downregulated in the melanoma developing medaka. High-
dose interferon has been used for nearly two decades as adjuvant treatment of patients with
melanoma who have undergone a complete surgical resection but who are considered to be at a
high risk of relapse. Evidence leading to interferon therapy was based on significantly improved
relapse-free survival and marginally improved overall survival. Subsequent large, randomized
trials have not been able to reproduce a benefit in overall survival, yet interferon treatment con-
tinues to be a first option for those patients [50]. Stat5, which was first identified as a mela-
noma-relevant gene in our fish melanoma model [51], is now used in the clinic to elucidate
mechanisms of resistance to interferon treatment in human patients [25]. Collectively, our net-
work inferred immune-system gene candidates could provide points of entry for therapeutics
to elevate the immune response of the host to progressing melanoma or conversely, to subdue
putative immunosuppression by malignant melanocytes. Such molecular insight will be chal-
lenging without our whole-body approach.
Importantly, our whole-body expression screen identified candidates for future drug
screens, in particular immunoregulatory molecules. Drug screen outcomes will require net-
work or systems biology interpretation because some genes participate in multiple pathways,
for example, phosphatidylinositol kinases act in leukocyte extravasation and antigen pattern
recognition pathways. A total of 11 aberrant medaka melanoma gene expression candidates
found in our study, some examples include aadac, dhdh, dusp13, and pik3r6, have experienced
missense (amino acid substitution) mutations in human melanoma genomes [52]. Despite the
unknown clinical relevance of these mostly missense mutations in melanoma patients, we sug-
gest further investigation of any drugs known to target these proteins translated from
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differentially expressed genes in our fish melanoma model, but not currently used to treat
human melanoma, is needed to test transcript outcome in isolation and synergy, i.e., drug com-
binations [29]. We contend that a reduced transcript network, that indirectly mimics the tran-
scriptional disease signature, could be used to cost effectively screen drugs in a high
throughput system.
In summary, building genetic networks that adequately represent whole body transcriptome
responses to invasive cancer is crucial to the exploration of secondary pathways for melanoma
suppression. Cancer genome-sequencing studies have identified recurring mutational signa-
tures in various cancers including melanoma, but the corresponding immunological signatures
of tumors are highly variable and are far from well understood. Closing this knowledge gap is
likely to be important, given that infiltration of immune cells into tumors is correlated with
positive prognoses [53, 54]. A better understanding of the complex interactions between cancer
cells and the immune system is likely to lead to improvements in current therapeutic
approaches and to spur the development of novel therapies. Our study 1) illustrates how focus-
ing only on the tumor itself might leave unknowns that are revealed when whole animals are
taken into account; 2) shows how the tumor can affect non-tumor body systems; and 3) pro-
vides insights into new potential therapeutic targets. The whole body transcriptome based
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